Stock Market Reviews

ASND (Ascendis Pharma A/S) News

Get the latest news, insights, and market updates on ASND (Ascendis Pharma A/S). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Rise 2% for Week
  European equities traded in the US as American depositary receipts were down late Friday morning, fa
  Jan 16, 2026 - $ASND
• Ascendis Pharma A/S (ASND): A Bull Case Theory
  We came across a bullish thesis on Ascendis Pharma A/S on Tip Ranks’ YouTube Channel. In this article, we will summarize the bulls’ thesis on ASND. Ascendis Pharma A/S’s share was trading at $215.05 as of January 13th. ASND’s forward P/E was 48.78, according to Yahoo Finance. Ascendis Pharma (ASND) is a biopharma company specializing in innovative […]
  Jan 15, 2026 - $ASND
• Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?
  Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
  Jan 14, 2026 - $ASND
• Ascendis Pharma A/S Touts €683M Product Revenue, Feb PDUFA Catalyst at JPM Healthcare Conference
  Ascendis Pharma A/S (NASDAQ:ASND) highlighted accelerating product revenue growth, expanding international commercialization, and multiple 2026 clinical and regulatory milestones during a presentation and Q&A at the 44th Annual J.P. Morgan Healthcare Conference. Revenue growth and profitability
  Jan 13, 2026 - $ASND
• Is Ascendis Pharma (ASND) Pricing Reflect Its DCF Versus Pipeline Progress And Regulatory Updates
  If you are wondering whether Ascendis Pharma's share price still reflects good value after its recent run, this article will walk through what the current market price might be implying about the company. The stock closed at US$208.76, and while the 7 day, 30 day and year to date returns of 0.3% decline, 5.3% decline and 2.1% decline may look mixed, the 1 year, 3 year and 5 year returns of 58.7%, 74.5% and 31.9% show a very different picture. Recent headlines around Ascendis Pharma have...
  Jan 13, 2026 - $ASND
• European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
  European equities traded in the US as American depositary receipts opened the week higher late Monda
  Jan 12, 2026 - $ASND
• What Ascendis Pharma (ASND)'s Phase 2 COACH Combo Data Means For Shareholders
  Earlier this week, Ascendis Pharma A/S reported Week 52 topline data from its Phase 2 COACH trial, showing that once-weekly TransCon CNP plus TransCon hGH in children with achondroplasia delivered durable growth gains, improved body proportionality and arm span, and maintained a safety profile consistent with monotherapy use. The results arrive as TransCon CNP is under Priority Review in the US and Europe and support Ascendis’s goal of positioning TransCon CNP as a backbone therapy in...
  Jan 12, 2026 - $ASND
• Ascendis Pharma COACH Week 52 data show combo TransCon CNP + hGH boosts growth in achondroplasia
  Ascendis Pharma A/S (NASDAQ:ASND) executives highlighted topline Week 52 results from the company’s Phase 2 COACH trial, which is evaluating a once-weekly combination regimen of TransCon CNP and TransCon Growth Hormone (TransCon hGH) in children with achondroplasia. Management said the one-year data
  Jan 9, 2026 - $ASND
• Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
  - Rapidly transforming into a leading global biopharma companyCOPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update on Monday, January 12, during the 44th Annual J.P. Morgan Healthcare Conference. “With our proven TransCon® technology platform, strong R&D capabilities, and a maturing commerci
  Jan 9, 2026 - $ASND
• Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
  – Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-percentile of average stature children – ACH height Z-score improvements indicated a tripling of efficacy compared to TransCon CNP monotherapy – Combination therapy demonstrated benefits beyond linear growth with improvements in body proportionality and arm span, aligning with the increase in linear gr
  Jan 8, 2026 - $ASND